GSK and Verily Form Joint Venture to Develop Bioelectronic Medicines | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

GSK and Verily Form Joint Venture to Develop Bioelectronic Medicines

August 1, 2016
by Heather Landi
| Reprints

U.K.-based pharmaceutical company GlaxoSmithKline (GSK) is forming a joint venture with Verily Life Sciences, which is owned by Google parent company Alphabet, to research, develop and commercialize bioelectronics medicines.

The companies announced this week the new venture, Galvani Bioelectronics. GSK will hold a 55 percent equity interest in the new jointly owned company and Verily, which was formerly Google Life Sciences, will hold 45 percent equity interest.

Galvani Bioelectronics will be headquartered in the U.K., with the parent companies contributing existing intellectual property rights and an investment of up to 540 million pounds ($715 million) over seven years, subject to successful completion of various discovery and development milestones, the companies stated in a press release.

Bioelectronic medicine is a relatively new field that aims to tackle a wide range of chronic diseases using miniature, implanted devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses, according to the press release. GSK has been active in this field since 2012 and the company is betting that certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices.

The new company will bring together GSK’s drug discovery and development expertise and work in disease biology with Verily’s technical expertise in the miniaturization of low power electronics, device development, data analytics and software development for clinical applications, the companies said.

“Initial work will center on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where substantial evidence already exists in animal models; and developing associated miniaturized, precision devices,” the companies stated.

Galvani Bioelectronics will initially employ around 30 scientists, engineers and clinicians, and will fund and integrate a broad range of collaborations with both parent companies, academia and other R&D companies.

Kris Famm, GSK’s vice president of bioelectronics R&D, has been appointed president of the new company. Famm has co-designed and led GSK’s work in bioelectronics and since 2012, scientists at GSK have been researching the potential of bioelectronic medicines. In that time, the company has established a global network of around 50 research collaborations and investing $50 million in a dedicated bioelectronics venture capital fund.

Galvani Bioelectronics is named after Luigi Aloisio Galvani, an 18th century Italian scientist, physician and philosopher, who was one of the first to explore the field of bioelectricity.


Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More



Study: EHRs Tied with Lower Hospital Mortality, But Only After Systems Have Matured

Over the past decade, there has been significant national investment in electronic health record (EHR) systems at U.S. hospitals, which was expected to result in improved quality and efficiency of care. However, evidence linking EHR adoption to better care is mixed, according to medical researchers.

Nursing Notes Can Help Predict ICU Survival, Study Finds

Researchers at the University of Waterloo in Ontario have found that sentiments in healthcare providers’ nursing notes can be good indicators of whether intensive care unit (ICU) patients will survive.

Health Catalyst Completes Acquisition of HIE Technology Company Medicity

Salt Lake City-based Health Catalyst, a data analytics company, has completed its acquisition of Medicity, a developer of health information exchange (HIE) technology, and the deal adds data exchange capabilities to Health Catalyst’s data, analytics and decision support solutions.

Advocate Aurora Health, Foxconn Plan Employee Wellness, “Smart City,” and Precision Medicine Collaboration

Wisconsin-based Advocate Aurora Health is partnering with Foxconn Health Technology Business Group, a Taiwanese company, to develop new technology-driven healthcare services and tools.

Healthcare Data Breach Costs Remain Highest at $408 Per Record

The cost of a data breach for healthcare organizations continues to rise, from $380 per record last year to $408 per record this year, as the healthcare industry also continues to incur the highest cost for data breaches compared to any other industry, according to a new study from IBM Security and the Ponemon Institute.

Morris Leaves ONC to Lead VA Office of Electronic Health Record Modernization

Genevieve Morris, who has been detailed to the U.S. Department of Veterans Affairs (VA) from her position as the principal deputy national coordinator for the Department of Health and Human Services, will move over full time to lead the newly establishment VA Office of Electronic Health Record Modernization.